Guidance Blitz: 1,090 Bps Margin Miss as Credibility Craters
Management blamed external biotech constraints for a 22% revenue drop and ₹67 crore loss, but the core problem is structural: CDMO margins collapsed from 25% to 12%, and a half-decade of guidance misses now complete. FY28–29 targets promise 20–21% margins. The street is fleeing.
₹507.4 Cr
-22.3% YoY
-₹66.7 Cr
NPM -13.1%
9.1%
vs 19.5–20% FY26 guided
12.3%
vs 25% prior year
Dishman Carbogen Amcis delivered its worst quarter in 2.5 years—and blamed it on headwinds everyone can see: biotech funding dried up, molecules aren't moving, and because the cost base is 70% fixed, revenue defers straight through to the bottom line. What's harder to defend is this: the firm had guided 19.5–20% EBITDA margins for FY26 and promised ₹500 crores in India revenue within 12–18 months. Both missed. Now it has reset FY27 guidance to 15–16% margins, with Q2 actual at 9.1%. It promises 20–21% margins again in FY28–29. The street is not convinced.
What actually happened
Revenue fell ₹143 crores year-on-year, driven by a collapse in molecule development work. The CDMO business, supposed to be the margin engine, delivered 12.3% margins this quarter—down from 25% a year ago. Marketable Molecules did not fare better, compressing from 21% (H1 prior year) to 8.7% (H1 this year), courtesy of a shift away from higher-margin vitamin D analogs toward lower-margin cholesterol products. With ₹46 crores in EBITDA on ₹507 crores revenue—a 9.1% operating margin—and ₹40 crores in quarterly interest costs, the company swung to a ₹67 crore net loss. No one-time items. Organic collapse.
Market trends slightly upwards; early-phase projects showing interest
ContradictedDevelopment revenue declined sharply; projects deferred due to biotech funding constraints
CDMO margins stable; optimization underway
ContradictedCDMO margins fell from 25% to 12.3% YoY; Marketable Molecules 21% to 8.7% H1 YoY
Order book building for H2 and next year
PartialQ2 -22% revenue; H1 ₹1,185 Cr vs ₹1,360 Cr prior. Orders deferred, not new.
Bavla facility achieving significant cost leverage
OverstatedBavla still in infrastructure/setup phase. Targeting ₹150 Cr quarterly but no timeline given.
EBITDA margin FY27 on track to 15–16%
OverstatedQ2 OPM 9.1%, H1 EBITDA ₹106 Cr on ₹1,185 Cr = 8.9%. Path suggests miss.
What changed on this call
FY27 EBITDA margin guidance cut from 19.5–20% (FY26 guided) to 15–16%
Biotech funding constraints emerged as new structural headwind, not cyclical blip
Bavla facility ramp timeline pushed out again; no specific revenue materialization date
On the medium-term side, management introduced FY28–29 targets: 10–12% revenue growth and 20–21% EBITDA margins, contingent on three catalysts. First: tech transfer validation batches due March–April 2027, projected CHF 25–30 million annualized revenue from 3 commercial and 2 intermediate transfers. Second: Bavla facility ramp to ₹150 crores quarterly run-rate, underpinned by a Japanese customer co-investment (100 metric tons) and big pharma partnerships. Third: ECB drawdown completion in Q4, reducing quarterly interest costs from ₹40 crores to ₹20–25 crores. All forward-looking. Near-term upside is minimal.
How the street read it
The stock was worth ₹396.4 at its all-time high. It now trades at ₹115.57—a 71% drawdown. FII ownership collapsed from 9.93% (Q1 FY26) to 6.97% (Q2 FY27), a 296 basis point exit. The RSI sits at 27.4, deep oversold, yet the stock is still below its 20-day, 50-day, and 200-day simple moving averages. Volume is increasing—a sign of capitulation selling. The street's verdict is unambiguous: credibility is gone, and the medium-term targets are not believed. Even at oversold levels, buyers are absent.
Long-term CDMO market tailwind; biotech outsourcing structural
Tech transfer pipeline (CHF 25–30M annually) if validated and deployed
ECB interest cost drop (₹40 Cr → ₹20–25 Cr quarterly) is a known positive
FY26 margin and ₹500 Cr India revenue targets both missed; credibility at zero
CDMO margins halved; fixed cost base shows no flexibility
Bavla ramp-up without timeline; ROI unproven after 20+ years of investment
Reported worst quarter in 2.5 years; near-term catalysts are all H2 FY27+
Guidance credibility erosion
CriticalFY26 margin (19.5–20%) and revenue (₹500 Cr India in 12–18m) targets both missed. FY27 margin guidance (15–16%) is now at risk (H1 actual 8.9%). If FY27 misses, FY28–29 targets lose all credibility.
Biotech funding cycle dependency
HighMolecule development revenue stalled; orders deferred. If biotech funding does not recover by H2 FY27, full-year revenue will undershoot ₹2,900 Cr prior year. No visibility into recovery timeline.
Fixed cost base inflexibility
High~70% of costs fixed. Margin halved from 25% to 12% despite revenue decline. If molecule development or CDMO volumes stay soft, margins will stay compressed even with flat costs.
Tech transfer execution delay
HighValidation batches scheduled April 2027; regulatory and technical delays are routine in CDMO. Any slip pushes revenue 3–6+ months. CHF 25–30M annual run-rate is 3–4% of revenue; delay dents credibility further.
Bavla facility ROI timeline
MediumCapex completed but facility underutilized. ₹150 Cr quarterly run-rate target has no timeline. If ramp-up takes 2–3+ years, cumulative ROI erodes. Japanese and big pharma partnerships are pre-binding.
1 · Q3 FY27 revenue trend (H2 visibility)
Orders are deferred to H2, not cancelled. If Q3 shows sequential recovery or deferred orders materializing, the "biotech funding trough" narrative holds. If Q3 is flat or declining, structural demand weakness becomes the concern. Track: Q3 revenue vs. Q2 ₹507 Cr.
2 · Tech transfer validation results (April 2027)
Three commercial and two intermediate transfers in validation. If pilot runs succeed and clients move to commercial, it validates the ₹25–30M annualized revenue thesis and de-risks FY28 growth. If validation is delayed or fails, tech transfer becomes a 2028+ story, not FY27.
3 · FY27 full-year EBITDA margin (Q4 close)
Guidance is 15–16%; H1 delivered 8.9%. H2 must average ~20–22% margins to hit 15–16% for the year. This requires significant margin expansion in Q3 or Q4. If H2 margins stay sub-10%, management misses guidance for the third straight year. Track: FY27 actual EBITDA margin vs. 15–16% guided.
Dishman is at an inflection point. The near-term story is a trough quarter with deferred orders. The medium-term story is a leveraged bet on Bavla ramp, tech transfers, and molecule recovery. Both are plausible. But the firm has reset guidance twice in two years—from 19.5–20% margins (FY26) to 15–16% (FY27), now betting on 20–21% (FY28–29). At ₹115, the stock is a speculative opportunity for those who believe management can execute the medium-term plan. But credibility is on trial. The honest read is not "buy the dip." It's wait for validation. The number to track from here is Q3 revenue (is H2 recovery real?) and Q4 EBITDA margin (can the firm hit 15–16% FY27, or miss again?). Until Dishman delivers against guided FY27 targets, the medium-term thesis is a belief, not a fact.
Informational and educational content only. Not investment advice.